TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE

1 .- 45 . (canceled)

46 . A dispersible tablet comprising:

(i) about 30% to about 70% by weight of Compound 1 of formula:

(ii) filler;

(iii) disintegrant;

(iv) glidant; and

(v) a lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

47 . A dispersible tablet comprising:

(i) about 30% to about 70% by weight of Compound 1 of formula:

(ii) a filler;

(iii) a disintegrant;

(iv) a glidant;

(v) a lubricant;

(vi) a surfactant; and

(vii) optionally a binder;

wherein the amount of disintegrant to filler is in a ratio of about 1:28, and wherein the percentage by weight is relative to the total weight of the tablet.

48 . A tablet comprising:

(i) about 30% to about 70% by weight of Compound 1 of formula:

(ii) a filler;

(iii) less than about 2% by weight of disintegrant;

(iv) a glidant;

(v) a lubricant;

(vi) a surfactant; and

(vii) optionally a binder;

wherein the amount of disintegrant to filler is in a ratio of about 1:28 and wherein the percentage by weight is relative to the total weight of the tablet.

49 . A dispersible tablet comprising:

(i) 60%±5% by weight of crystalline Compound 1 of formula:

wherein crystalline Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 20);

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloidal silicon dioxide;

(v) about 1% to about 5% by weight of magnesium stearate;

(vi) a sweetener;

(vii) a flavoring agent; and

(viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet and wherein the dispersible tablet disintegrates in a liquid in less than 1 minute.

50 . A method of treating sickle cell disease in a patient, wherein the method comprises administering to the patient one or more of a dispersible tablet of claim 46 .

51 .- 57 . (canceled)

58 . The dispersible tablet of claim 46 , comprising:

(i) about 50% to about 70% by weight of Compound 1;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and

(v) about 1% to about 5% by weight of lubricant.

59 . The dispersible tablet of claim 58 , further comprising:

(vi) a sweetener;

(vii) a flavoring agent; and

(viii) a coloring agent.

60 . The dispersible tablet of claim 46 , comprising:

(i) about 50% to about 70% by weight of Compound 1;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) about 1% to about 5% by weight of lubricant;

(vi) optionally about 1% to about 3% by weight of sweetener;

(vii) optionally about 0.2% to about 1.5% by weight of flavoring agent; and

(viii) optionally about 0.1% to about 1% by weight of coloring agent.

61 . The dispersible tablet of claim 60 , wherein the filler is microcrystalline cellulose.

62 . The dispersible tablet of claim 60 , wherein the disintegrant is croscarmellose sodium.

63 . The dispersible tablet of claim 60 , wherein the glidant is colloidal silicon dioxide.

64 . The dispersible tablet of claim 60 , wherein the lubricant is magnesium stearate.

65 . The dispersible tablet of claim 60 , wherein the sweetener is sucrose, xylitol, maltitol, mannitol, sorbitol, sucralose, sodium saccharin, acesulfame potassium, or aspartame.

66 . The dispersible tablet of claim 46 , comprising:

(i) about 50% to about 70% by weight of Compound 1;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloidal silicon dioxide;

(v) about 1% to about 5% by weight of magnesium stearate;

(vi) optionally about 1% to about 3% by weight of sweetener;

(vii) optionally about 0.2% to about 1.5% by weight of flavoring agent; and

(viii) optionally about 0.1% to about 1% by weight of coloring agent.

67 . The dispersible tablet of claim 66 , wherein the tablet comprises Compound 1 in an amount of about: 300 mg, 450 mg, 600 mg, 750 mg, 900 mg, 1200 mg, or 1500 mg.

68 . The dispersible tablet of claim 66 , wherein the tablet comprises Compound 1 in an amount of about 300 mg.

69 . The dispersible tablet of claim 46 , wherein the amount of disintegrant to filler is in a ratio of about 1:28.

70 . A dispersible tablet comprising:

(i) 60%±5% by weight of Compound 1 of formula:

(ii) 20% to 35% by weight of microcrystalline cellulose;

(iii) 1% to 2% by weight of croscarmellose sodium;

(iv) less than 2% by weight of colloidal silicon dioxide;

(v) 1% to about 5% by weight of magnesium stearate;

(vi) a sweetener;

(vii) a flavoring agent; and

(viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

71 . The dispersible tablet of claim 70 , wherein Compound 1 is in a crystalline ansolvate form characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 20).

72 . A dispersible tablet comprising:

(i) an intragranular component comprising:

(a) about 58% by weight of Compound 1 of formula:

(b) about 26% by weight of microcrystalline cellulose;

(c) about 1% by weight of croscarmellose sodium;

(d) about 1.5% by weight of magnesium stearate;

(e) about 0.5% by weight of colloidal silicon dioxide; and

(ii) an extragranular component comprising:

(a) about 8% by weight of microcrystalline cellulose;

(b) about 0.25% by weight of croscarmellose sodium;

(c) about 0.8% by weight of magnesium stearate;

(d) about 2.5% by weight of sucralose;

(e) about 0.2% by weight of colloidal silicon dioxide;

wherein the percentage by weight is relative to the total weight of the tablet.

73 . The dispersible tablet of claim 72 , wherein Compound 1 is in a crystalline ansolvate form characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 20).

74 . The dispersible tablet of claim 72 , wherein the extragranular component further comprises artificial grape flavor.

75 . The dispersible tablet of claim 72 , wherein the extragranular component further comprises iron oxide pigment.

76 . The method of claim 50 , wherein the dispersible tablet is dispersed in a liquid prior to its administration to the patient.